New obesity shot for teens enters early safety trial
NCT ID NCT07559136
First seen May 01, 2026 · Last updated May 10, 2026 · Updated 2 times
Summary
This early-stage trial tests a new injection called HRS9531 in Chinese adolescents aged 12 to 17 who have obesity. The study compares the drug to a placebo to check its safety and how the body processes it. About 48 participants will join, and they must have been on a stable diet and exercise plan for at least 12 weeks before starting. The goal is to see if the drug is safe and how it affects weight and body measurements.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
Contact
Conditions
Explore the condition pages connected to this study.